Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 5/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.36 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25820301 | 0.86 | OPRM1 (0.33) | OPRM1HSD11B1 | |
| SCHEMBL25001588 | 0.79 | HSD11B1 (0.31) | HSD11B1 | |
| SCHEMBL18202941 | 0.79 | HSD11B1 (0.33) | OPRM1HSD11B1 | |
| SCHEMBL18459239 | 0.73 | HSD11B1 (0.38) | HSD11B1 | |
| SCHEMBL18202957 | 0.72 | KDM1A (0.33) | OPRM1HSD11B1 | |
| SCHEMBL18202931 | 0.72 | OPRM1 (0.36) | OPRM1HSD11B1 | |
| SCHEMBL25001378 | 0.71 | USP2 (0.30) | — | |
| SCHEMBL21337271 | 0.70 | MEN1 (0.31) | ALDH1A1 | |
| SCHEMBL25094688 | 0.70 | OPRM1 (0.38) | OPRM1ALDH1A1 | |
| SCHEMBL19276538 | 0.69 | ACHE (0.43) | OPRM1NPSR1HSD11B1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230219986-A1 | NOVEL AMINOPYRIMIDINE EGFR INHIBITOR | QILU PHARMACEUTICAL CO., LTD. (CN) | 2023-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219986-A1 | NOVEL AMINOPYRIMIDINE EGFR INHIBITOR | EGFR, ERBB2, ERBB4 | OPRM1 3589/4885NPSR1 3444/4885HSD11B1 4623/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.